Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles

Journal of Drug Targeting

Volumn 24, Issue 9, 2016, Pages 780-786

  Ramishetti, Srinivas ^a   Landesman Milo, Dalit ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Ionizable lipids; leukocytes; lipid nanoparticles; microfluidic mixing; siRNA

Indexed keywords

LIPID; NANOPARTICLE; SMALL INTERFERING RNA;

B LYMPHOCYTE; DENDRITIC CELL; GENE SILENCING; LEUKOCYTE; LYMPHOCYTE; MACROPHAGE; MICROFLUIDICS; MONOCYTE; MONONUCLEAR PHAGOCYTE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; RNAI THERAPEUTICS; T LYMPHOCYTE; CHEMISTRY; GENE THERAPY; GENE TRANSFER; PROCEDURES; RNA INTERFERENCE;

GENE TRANSFER TECHNIQUES; GENETIC THERAPY; LIPIDS; NANOPARTICLES; RNA INTERFERENCE;

EID: 84965081966     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2016.1172587     Document Type: Review

References (68)

1. Jain NK, Mishra V, Mehra NK., Targeted drug delivery to macrophages. Expert Opin Drug Deliv 2013;10:353–67.
2. Chow A, Brown BD, Merad M., Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol 2011;11:788–98.
3. Murray PJ, Wynn TA., Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723–37.
4. Shi C, Pamer EG., Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011;11:762–74
5. Kelly C, Jefferies C, Cryan SA., Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011;2011:727241.
6. Bloy N, Pol J, Aranda F, et al. Trial watch:dendritic cell-based anticancer therapy. Oncoimmunology 2014;3:e963424.
7. Amoozgar Z, Goldberg MS., Targeting myeloid cells using nanoparticles to improve cancer immunotherapy. Adv Drug Deliv Rev 2015;91:38–51.
8. Palucka K, Banchereau J., Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265–77.
9. Joaõ Conde CEA., Furong Tian and Natalie Artzi. RNAi nanomaterials targeting immune cells as an anti-tumor therapy:the missing link in cancer treatment? Mater Today 2015;19:29–43.
10. Peer D., A daunting task:manipulating leukocyte function with RNAi. Immunol Rev 2013;253:185–97.
11. Lee L, Gupta M, Sahasranaman S., Immune checkpoint inhibitors:an introduction to the next-generation cancer immunotherapy. J Clin Pharmacol 2016;56:157–69.
12. Behlke MA., Progress towards in vivo use of siRNAs. Mol Ther 2006;13:644–70.
13. Daka A, Peer D., RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 2012;64:1508–21.
14. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494–8.
15. Shi Y., Mammalian RNAi for the masses. Trends Genet 2003;19:9–12.
16. Peer D., Harnessing RNAi nanomedicine for precision therapy. Mol Cell Ther 2014;2:5.
17. Peer D., Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles:a mini-review. J Control Release 2010;148:63–8.
18. Ramishetti S, Kedmi R, Goldsmith M, et al. Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 2015;9:6706–16.
19. Zhou J, Neff CP, Liu X, et al. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther 2011;19:2228–38.
20. Peer D, Zhu P, Carman CV, et al. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci Unit States Am 2007;104:4095–100.
21. Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008;16:1481–9.
22. Wheeler LA, Trifonova R, Vrbanac V, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Investig 2011;121:2401–12.
23. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709–17.
24. Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577–86.
25. Weinstein S, Toker IA, Emmanuel R, et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci Unit States Am 2016;113:E16–22.
26. Peer D, Park EJ, Morishita Y, et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319:627–30.
27. Kanasty R, Dorkin JR, Vegas A, Anderson D., Delivery materials for siRNA therapeutics. Nat Mater 2013;12:967–77.
28. Peer D, Lieberman J., Special delivery:targeted therapy with small RNAs. Gene Ther 2011;18:1127–33.
29. Landesman-Milo D, Peer D., Toxicity profiling of several common RNAi-based nanomedicines:a comparative study. Drug Deliv Trans Res 2014;4:96–103.
30. Robbins M, Judge A, Ambegia E, et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008;19:991–9.
31. Behlke MA., Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305–19.
32. Kedmi R, Ben-Arie N, Peer D., The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation. Biomaterials 2010;31:6867–75.
33. Goldsmith M, Mizrahy S, Peer D., Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine (Lond) 2011;6:1771–85.
34. Weinstein S, Emmanuel R, Jacobi AM, et al. RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. PloS One 2012;7:e43343.
35. Freeley M, Long A., The two hit hypothesis:an improved method for siRNA-mediated gene silencing in stimulated primary human T cells. J Immunol Meth 2013;396:116–27.
36. Freeley M, Long A., Advances in siRNA delivery to T-cells:potential clinical applications for inflammatory disease, cancer and infection. Biochem J 2013;455:133–47.
37. Herrmann A, Priceman SJ, Swiderski P, et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Investig 2014;124:2977–87.
38. Wheeler LA, Vrbanac V, Trifonova R, et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther 2013;21:1378–89.
39. Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 2012;51:8529–33.
40. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28:172–6.
41. Novobrantseva TI, Borodovsky A, Wong J, et al. Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucleic Acids 2012;1:e4.
42. Heyes J, Palmer L, Bremner K, MacLachlan I., Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 2005;107:276–87.
43. Zuhorn IS, Bakowsky U, Polushkin E, et al. Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency. Mol Ther 2005;11:801–10.
44. Hafez IM, Maurer N, Cullis PR., On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 2001;8:1188–96.
45. Zhang J, Fan H, Levorse DA, Crocker LS., Ionization behavior of amino lipids for siRNA delivery:determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions. Langmuir 2011;27:1907–14.
46. Ramishetti S, Huang L., Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv 2012;3:1429–45.
47. Petros RA, DeSimone JM., Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010;9:615–27.
48. Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. Silence 2010;1:14.
49. Yona S, Jung S., Monocytes:subsets, origins, fates and functions. Curr Opin Hematol 2010;17:53–9.
50. Basha G, Novobrantseva TI, Rosin N, et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther 2011;19:2186–200.
51. Foged C, Brodin B, Frokjaer S, Sundblad A., Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharmaceut 2005;298:315–22.
52. Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci Unit States Am 2010;107:1864–9.
53. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011;29:1005–10.
54. Benson DM, Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect:a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116:2286–94.
55. Iwai Y, Terawaki S, Ikegawa M, et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 2003;198:39–50.
56. Dolina JS, Sung SS, Novobrantseva TI, et al. Lipidoid nanoparticles containing PD-L1 siRNA delivered in vivo enter Kupffer cells and enhance NK and CD8(+) T cell-mediated hepatic antiviral immunity. Mol Ther Nucleic Acids 2013;2:e72.
57. Avogadri F, Wolchok JD., Selecting antigens for cancer vaccines. Nat Biotechnol 2012;30:328–9.
58. Hobo W, Novobrantseva TI, Fredrix H, et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother 2013;62:285–97.
59. Srinivas R, Garu A, Moku G, et al. A long-lasting dendritic cell DNA vaccination system using lysinylated amphiphiles with mannose-mimicking head-groups. Biomaterials 2012;33:6220–9.
60. Katakowski JA, Mukherjee G, Wilner SE, et al. Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses. Mol Ther 2016;24:146–55.
61. Sharma P, Allison JP., Immune checkpoint targeting in cancer therapy:toward combination strategies with curative potential. Cell 2015;161:205–14.
62. Srinivasan C, Peer D, Shimaoka M., Integrin-targeted stabilized nanoparticles for an efficient delivery of siRNAs in vitro and in vivo. Methods Mol Biol 2012;820:105–16.
63. Kim SS, Peer D, Kumar P, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2010;18:370–6.
64. He W, Bennett MJ, Luistro L, et al. Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability. Mol Ther 2014;22:359–70.
65. Belliveau NM, Huft J, Lin PJ, et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids 2012;1:e37.
66. Zhigaltsev IV, Belliveau N, Hafez I, et al. Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir 2012;28:3633–40.
67. Leung AK, Hafez IM, Baoukina S, et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J Phys Chem C Nanomater Interfaces 2012;116:18440–50.
68. Leung AK, Tam YY, Chen S, et al. Microfluidic mixing:a general method for encapsulating macromolecules in lipid nanoparticle systems. J Phys Chem B 2015;119:8698–706.